Analytical Data
-
Gene name
IFN-gamma
- Application
-
Biological Activity
1.The ED50 is <0>2 × 106 units/mg. 2.Measured by its binding ability in a functional ELISA. Immobilized rat IFN gamma at 10 μg/mL (100 μL/well) can bind biotinylated rat IFN gamma R1. The ED50 for this effect is 35.05 ng/mL. Measured by its binding ability in a functional ELISA. Immobilized rat IFN gamma at 10 μg/ml (100 μL/well) can bind biotinylated rat IFN gamma R1. The ED50 for this effect is 35.05 ng/mL.
-
Alternative Names
rRtIFN-γ; IFNG; IFN-gamma; Interferon gamma
-
Species
Rat
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
P01581
-
Expression Region
G24-C156
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
14 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon-gamma (IFN-γ) is a crucial cytokine in the immune system, primarily produced by T cells and natural killer (NK) cells. It plays a vital role in modulating immune responses, enhancing the anticancer and antiviral activity of immune cells, and promoting antigen presentation. Given its importance in various immune-related disorders, including autoimmune diseases, cancer, and infections, recombinant IFN-γ has been extensively researched for therapeutic applications. Historically, IFN-γ was first identified for its ability to inhibit viral replication and regulate the expression of major histocompatibility complex (MHC) molecules. Subsequent studies have demonstrated its potential in enhancing the immune response against tumors and pathogens, making it a candidate for treatment in diseases such as chronic granulomatous disease and certain types of cancer. Researchers have focused on developing stable recombinant proteins that mimic natural IFN-γ to harness its therapeutic benefits. Advanced biotechnological methods, including genetic engineering and expression systems, have been employed to produce IFN-γ in sufficient quantities for clinical use. Ongoing investigations are aimed at understanding its mechanisms of action, optimizing its production, and developing novel delivery methods, further underscoring the significance of IFN-γ in immunotherapy and vaccine development. The continued exploration of IFN-γ and its applications represents a promising frontier in both basic research and clinical practices within the field of immunology.
